04 · Five things to know · 02
Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer
Must read
Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer. In 61 patients, 60.7% had a confirmed response and median progression-free survival was 12.8 months. Another single-arm result. The randomized test against chemotherapy alone, RASolute 303, has not read out.
From the edition's At a glance, as printed.
Bookmarks need a Mind Club sign-in. How sign-in works
Read it in Five things to know